Skip to main content
MarketStoryBook
All storiesBAYN.DE in “America Imports the World's Drug Prices”BAYN.DE in storiesBAYN.DE stock

BAYN.DE in “America Imports the World's Drug Prices”

Bayer Aktiengesellschaft

Bear sideStableExposure: not rated yet

Bayer's growth drugs, including Nubeqa and Kerendia, face lower lifetime revenue potential if US reimbursement is benchmarked against discounted overseas prices.

BAYN.DE impact map — “America Imports the World's Drug Prices”

How this story travels from the headline to BAYN.DE’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.

Loading BAYN.DE impact map…

Price history, marked with story events

Oct 13, 2025 – Oct 14, 2026 · 255 sessions

Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions

Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…

Full story

America Imports the World's Drug Prices

US reference pricing puts global blockbuster economics—and not just American list prices—under pressure.

BEAR side — Bayer's growth drugs, including Nubeqa and Kerendia, face lower lifetime revenue potential if US reimbursement is benchmarked against discounted overseas prices.

Read the full America Imports the World's Drug Prices story

Bull side

0 stories

No bull-side stories for BAYN.DE yet.

Bear side

2 stories

  • BAYN.DE in “America Imports the World's Drug Prices”

    StableExposure: not rated yet
    Viewing

    US reference pricing puts global blockbuster economics—and not just American list prices—under pressure.

    Bayer's growth drugs, including Nubeqa and Kerendia, face lower lifetime revenue potential if US reimbursement is benchmarked against discounted overseas prices.

  • The Patent Cliff Sparks a Biotech Land Grab

    BAYN.DE in “The Patent Cliff Sparks a Biotech Land Grab”

    FadingExposure: not rated yet

    Large drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.

    Patent erosion in major pharmaceutical franchises collides with balance-sheet and litigation constraints, limiting Bayer's ability to compete freely for scarce replacement assets.